Latanoprost

• Open-angle glaucoma
• Ocular hypertension
• First-line IOP reduction
• Normal-tension glaucoma

Latanoprost, originally marketed as Xalatan and now widely available as a generic ophthalmic solution, is a once-daily prostaglandin F2-alpha analog that lowers intraocular pressure (IOP) in patients with primary open-angle glaucoma, normal-tension glaucoma, pseudoexfoliative glaucoma, and ocular hypertension. Because it produces a 25–35% IOP reduction with minimal systemic side effects and a single evening drop, it remains the first-line topical agent recommended by the American Academy of Ophthalmology Preferred Practice Pattern. Glaucoma is a leading global cause of irreversible blindness, and lowering IOP is the only modifiable factor known to slow disease progression — making consistent daily use of latanoprost a vision-preserving intervention rather than a symptomatic treatment.

Mechanism of Action

Latanoprost is an inactive isopropyl ester prodrug. After application, corneal esterases hydrolyze it within minutes to latanoprost acid, a selective FP-prostanoid receptor agonist. Activation of FP receptors in the ciliary body triggers remodeling of the extracellular matrix in the ciliary muscle and sclera, lowering resistance to aqueous humor drainage along the uveoscleral (unconventional) outflow pathway, which normally accounts for only a small fraction of total outflow but can be substantially upregulated. Some increase in trabecular outflow has also been demonstrated through similar matrix remodeling at the trabecular meshwork. Importantly, latanoprost does not reduce aqueous humor production — distinguishing it from beta-blockers (timolol-ophthalmic) and carbonic anhydrase inhibitors. The pharmacologic action begins within 3–4 hours of dosing, peaks around 8–12 hours, and reaches plateau efficacy after about four weeks of continuous use. The drug's localized prodrug activation and rapid systemic clearance explain why systemic adverse effects, even in patients with cardiopulmonary comorbidities, are minimal compared with topical beta-blockers that can provoke bronchospasm or bradycardia.

Clinical Use

First-line monotherapy with a prostaglandin analog is the standard initial approach for most patients with newly diagnosed open-angle glaucoma or significant ocular hypertension. Latanoprost is competitive with related prostaglandins (bimatoprost, travoprost, tafluprost) on efficacy; selective laser trabeculoplasty (SLT) is an alternative or first-line option supported by the LiGHT trial, which demonstrated comparable IOP control and quality of life with the procedure. When monotherapy does not bring IOP to target, latanoprost is commonly combined with timolol-ophthalmic (often as a fixed combination), brimonidine, or a topical carbonic anhydrase inhibitor; fixed-combination products improve adherence and reduce drop burden. Patients on multiple drops should be assessed for adherence — complex regimens are a leading cause of glaucoma progression, and surveys consistently show adherence rates below 60% in real-world use. Comorbid conditions like diabetes-mellitus and uncontrolled hypertension can accelerate optic nerve damage and should be optimized in parallel; sleep apnea, obstructive vascular disease, and migraine with vasospasm have also been linked to glaucoma progression. See also our internal-medicine/ophthalmology overview for context on coordinated eye and systemic care.

How to Take It

Use one drop in the affected eye(s) once daily in the evening. Evening dosing aligns with the diurnal IOP curve, which peaks in the early morning hours, providing maximal pressure-lowering when it matters most. More frequent dosing actually reduces effectiveness through receptor downregulation — once daily is a hard maximum. Wash hands before instillation, tilt the head back, pull the lower lid down, and place a single drop in the conjunctival sac without touching the dropper to the eye, eyelashes, or fingers (which causes contamination and infection risk). Close the eye gently and apply punctal occlusion (light pressure on the inner corner of the eye against the side of the nose) for 1–2 minutes — this reduces systemic absorption through the nasolacrimal duct and improves ocular contact time, both increasing efficacy and reducing the small risk of systemic side effects. If using other eye drops, separate them by at least five minutes so the first drop is not washed away. Remove contact lenses before dosing and reinsert after 15 minutes, since the benzalkonium chloride preservative can be absorbed by lenses. Refrigerate unopened bottles; once opened, they may be kept at room temperature for up to six weeks, then should be discarded.

Monitoring and Follow-Up

IOP should be rechecked 4–6 weeks after starting therapy to confirm response, then every 3–6 months once stable. The ophthalmologic exam at each visit also assesses optic disc appearance, visual fields with standard automated perimetry, and retinal nerve fiber layer thickness on optical coherence tomography (OCT) — together these define progression more sensitively than IOP alone. Target IOP is individualized — typically a 20–30% reduction from baseline, with lower targets for advanced disease, faster progression, or thinner central corneal thickness. If response is inadequate after a full month at correct dosing, switching within the prostaglandin class or adding a second agent is reasonable; non-response to one prostaglandin does not always predict non-response to another. Patients should be counseled to expect gradual iris darkening (most likely in mixed-color irises, occurring over months to years), eyelash lengthening, thickening, and darkening, and possible periorbital skin pigmentation; the iris change is permanent while eyelash and skin changes typically reverse on discontinuation. Periorbital fat atrophy producing a sunken eye appearance has been described and may also be partially reversible. Although ophthalmology drives glaucoma care, primary care can support adherence and reinforce monitoring at each visit.

Special Populations

Safety in children has not been established for routine use, although ophthalmologists do prescribe latanoprost for pediatric glaucoma in selected cases under specialist supervision. Use during pregnancy is generally discouraged because prostaglandins can theoretically affect uterine activity, although systemic absorption from one drop is minimal — risk-benefit discussions with ophthalmology and obstetrics guide individual cases. Patients with active intraocular inflammation (uveitis), aphakia, pseudophakia with torn posterior capsule, or risk factors for cystoid macular edema should be monitored closely or considered for alternative therapy. A history of herpes simplex keratitis is a relative contraindication, as latanoprost may reactivate viral disease. Older adults tolerate the drug well and represent the largest treatment population; arthritis-related dexterity issues may complicate self-administration, in which case a caregiver, drop guide device, or autodropper can preserve adherence.

Drug Interactions and Practical Counseling

Systemic absorption is minimal, so meaningful systemic drug interactions are rare. The main local consideration is benzalkonium chloride, the preservative in standard latanoprost solutions, which can cause ocular surface irritation, dry eye, and contact lens damage; preservative-free formulations are available for sensitive patients. Topical NSAIDs (used after cataract surgery, for example) may blunt the IOP-lowering effect through prostaglandin pathway interference and should be timed apart. Patients using multiple eye drops should follow a consistent order — typically gel formulations last because they slow absorption of subsequent drops — with five-minute intervals between drops. Thimerosal-containing ophthalmic solutions can precipitate when mixed with latanoprost and require separation. There are no clinically significant systemic interactions warranting routine medication review beyond confirming there are no other ocular agents that overlap.

Glaucoma Co-Management

Glaucoma diagnosis and treatment selection sit with ophthalmology, but primary care has meaningful contributions. We screen for risk factors (family history, African or Hispanic ancestry, high myopia, prior eye trauma, chronic corticosteroid use), help control systemic conditions like obstructive sleep apnea and nocturnal hypotension that contribute to optic nerve injury, manage medications that may worsen glaucoma (anticholinergics, topiramate, sulfa-derivative drugs), and reinforce adherence at every visit. Patients on chronic corticosteroids — inhaled, intranasal, or systemic — should be reminded that steroid-induced IOP elevation can occur. The American Academy of Ophthalmology provides patient education materials in multiple languages, and our st-pete-sun-safety-eyes-skin-protection article addresses related ocular topics relevant to Florida residents.

When to Contact Your Doctor

Report sudden eye pain, marked redness, light sensitivity, sudden vision change, halos around lights (which may signal acute angle-closure glaucoma), or any new floaters or curtain over the visual field. Foreign-body sensation, mild stinging, and conjunctival hyperemia are common in the first weeks and usually do not require discontinuation, but worsening or persistent symptoms warrant evaluation. New eyelid swelling, discharge, or signs of infection should be assessed. The National Eye Institute maintains accessible patient resources on glaucoma and its treatment.

Glaucoma is a chronic, progressive disease in which adherence and timely follow-up directly preserve vision. If you have been newly diagnosed, are concerned about your current regimen, or have not had a comprehensive eye exam in over a year, contact us or schedule a visit to coordinate care with your eye specialist and address any systemic factors affecting your eye health.